OrbiMed To Raise $450 Million For Third Asia Life Science Fund

OrbiMed filed with the SEC to raise $450 million for its third Asia-focused fund, OrbiMed Asia Partners III L.P. Originally formed in 1989, OrbiMed maintains a strictly life science focus globally, with $13 billion under management and investments from early stage to private and public equity. The company opened offices in Shanghai and Mumbai in 2007 and now runs over $500 million in investments from its first two Asia funds. OrbiMed's Asia II partnership closed in 2014 with $325 million. The company says it considers investments in all sectors of life science, from biopharmaceuticals to medical devices, diagnostics and healthcare services.